Tumours can act as adjuvants for humoral immunity

D. M. Brown, T. L. Fisher, C. Wei, J. G. Frelinger, Edith M. Lord

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Tumour cells transfected with cDNAs encoding non-self proteins were used to investigate the ability of the immune system to respond to immunogenic antigens expressed by tumours. Secreted, intracellular and surface proteins were used as model antigens, as these reflect the potential forms of turnout antigens. Syngeneic BALB/c mice injected with viable line I lung carcinoma or EMT6 mammary tumour cells secreting ovalbumin (OVA) or prostate-specific antigen (PSA) produced very high immunoglobulin G (IgG) antibody titres, equivalent to those of mice injected with protein in Freund's complete adjuvant (FCA). Secretion of the antigens was not necessary as tumour cells expressing a cell-surface antigen (HER-2/Neu) or an intracellular antigen green fluorescence protein (GFP) - also generated high-titre antigen-specific IgG antibodies. In interleukin-4 (IL-4)-deficient mice, both IgG1 and IgG2a were produced in response to OVA administered in FCA, whereas in response to tumour-produced antigen, the antibodies switched from predominantly IgG1 to IgG2a, indicating that the mechanisms responsible for antibody induction differed between these forms of immunization. In contrast to the line 1 and EMT6 turnouts, which are of BALB/c origin, OVA- or PSA-producing B16 melanoma cells, which are of C57BL/6 origin, failed to elicit antibody production. This was not the result of strain differences, as a similar finding was observed when the turnouts were grown in (BALB/c × C57BL/6)F1 mice, but appeared to be caused by intrinsic differences in the tumours. Furthermore, co-injection of both B16/OVA and line 1 tumours resulted in production of anti-OVA antibody, indicating that B16 tumours were not immunosuppressive, but instead line 1 tumours appear to exert an adjuvant effect.

Original languageEnglish (US)
Pages (from-to)486-497
Number of pages12
JournalImmunology
Volume102
Issue number4
DOIs
StatePublished - Apr 30 2001

Fingerprint

Humoral Immunity
Ovalbumin
Antigens
Immunoglobulin G
Neoplasms
Freund's Adjuvant
Antibodies
Neoplasm Antigens
Prostate-Specific Antigen
Experimental Melanomas
Proteins
Surface Antigens
Immunosuppressive Agents
Interleukin-4
Antibody Formation
Anti-Idiotypic Antibodies
Immune System
Immunization
Membrane Proteins
Complementary DNA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Brown, D. M., Fisher, T. L., Wei, C., Frelinger, J. G., & Lord, E. M. (2001). Tumours can act as adjuvants for humoral immunity. Immunology, 102(4), 486-497. https://doi.org/10.1046/j.1365-2567.2001.01213.x

Tumours can act as adjuvants for humoral immunity. / Brown, D. M.; Fisher, T. L.; Wei, C.; Frelinger, J. G.; Lord, Edith M.

In: Immunology, Vol. 102, No. 4, 30.04.2001, p. 486-497.

Research output: Contribution to journalArticle

Brown, DM, Fisher, TL, Wei, C, Frelinger, JG & Lord, EM 2001, 'Tumours can act as adjuvants for humoral immunity', Immunology, vol. 102, no. 4, pp. 486-497. https://doi.org/10.1046/j.1365-2567.2001.01213.x
Brown, D. M. ; Fisher, T. L. ; Wei, C. ; Frelinger, J. G. ; Lord, Edith M. / Tumours can act as adjuvants for humoral immunity. In: Immunology. 2001 ; Vol. 102, No. 4. pp. 486-497.
@article{c4e21639a46c4cb4b93b79333b77f08c,
title = "Tumours can act as adjuvants for humoral immunity",
abstract = "Tumour cells transfected with cDNAs encoding non-self proteins were used to investigate the ability of the immune system to respond to immunogenic antigens expressed by tumours. Secreted, intracellular and surface proteins were used as model antigens, as these reflect the potential forms of turnout antigens. Syngeneic BALB/c mice injected with viable line I lung carcinoma or EMT6 mammary tumour cells secreting ovalbumin (OVA) or prostate-specific antigen (PSA) produced very high immunoglobulin G (IgG) antibody titres, equivalent to those of mice injected with protein in Freund's complete adjuvant (FCA). Secretion of the antigens was not necessary as tumour cells expressing a cell-surface antigen (HER-2/Neu) or an intracellular antigen green fluorescence protein (GFP) - also generated high-titre antigen-specific IgG antibodies. In interleukin-4 (IL-4)-deficient mice, both IgG1 and IgG2a were produced in response to OVA administered in FCA, whereas in response to tumour-produced antigen, the antibodies switched from predominantly IgG1 to IgG2a, indicating that the mechanisms responsible for antibody induction differed between these forms of immunization. In contrast to the line 1 and EMT6 turnouts, which are of BALB/c origin, OVA- or PSA-producing B16 melanoma cells, which are of C57BL/6 origin, failed to elicit antibody production. This was not the result of strain differences, as a similar finding was observed when the turnouts were grown in (BALB/c × C57BL/6)F1 mice, but appeared to be caused by intrinsic differences in the tumours. Furthermore, co-injection of both B16/OVA and line 1 tumours resulted in production of anti-OVA antibody, indicating that B16 tumours were not immunosuppressive, but instead line 1 tumours appear to exert an adjuvant effect.",
author = "Brown, {D. M.} and Fisher, {T. L.} and C. Wei and Frelinger, {J. G.} and Lord, {Edith M.}",
year = "2001",
month = "4",
day = "30",
doi = "10.1046/j.1365-2567.2001.01213.x",
language = "English (US)",
volume = "102",
pages = "486--497",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Tumours can act as adjuvants for humoral immunity

AU - Brown, D. M.

AU - Fisher, T. L.

AU - Wei, C.

AU - Frelinger, J. G.

AU - Lord, Edith M.

PY - 2001/4/30

Y1 - 2001/4/30

N2 - Tumour cells transfected with cDNAs encoding non-self proteins were used to investigate the ability of the immune system to respond to immunogenic antigens expressed by tumours. Secreted, intracellular and surface proteins were used as model antigens, as these reflect the potential forms of turnout antigens. Syngeneic BALB/c mice injected with viable line I lung carcinoma or EMT6 mammary tumour cells secreting ovalbumin (OVA) or prostate-specific antigen (PSA) produced very high immunoglobulin G (IgG) antibody titres, equivalent to those of mice injected with protein in Freund's complete adjuvant (FCA). Secretion of the antigens was not necessary as tumour cells expressing a cell-surface antigen (HER-2/Neu) or an intracellular antigen green fluorescence protein (GFP) - also generated high-titre antigen-specific IgG antibodies. In interleukin-4 (IL-4)-deficient mice, both IgG1 and IgG2a were produced in response to OVA administered in FCA, whereas in response to tumour-produced antigen, the antibodies switched from predominantly IgG1 to IgG2a, indicating that the mechanisms responsible for antibody induction differed between these forms of immunization. In contrast to the line 1 and EMT6 turnouts, which are of BALB/c origin, OVA- or PSA-producing B16 melanoma cells, which are of C57BL/6 origin, failed to elicit antibody production. This was not the result of strain differences, as a similar finding was observed when the turnouts were grown in (BALB/c × C57BL/6)F1 mice, but appeared to be caused by intrinsic differences in the tumours. Furthermore, co-injection of both B16/OVA and line 1 tumours resulted in production of anti-OVA antibody, indicating that B16 tumours were not immunosuppressive, but instead line 1 tumours appear to exert an adjuvant effect.

AB - Tumour cells transfected with cDNAs encoding non-self proteins were used to investigate the ability of the immune system to respond to immunogenic antigens expressed by tumours. Secreted, intracellular and surface proteins were used as model antigens, as these reflect the potential forms of turnout antigens. Syngeneic BALB/c mice injected with viable line I lung carcinoma or EMT6 mammary tumour cells secreting ovalbumin (OVA) or prostate-specific antigen (PSA) produced very high immunoglobulin G (IgG) antibody titres, equivalent to those of mice injected with protein in Freund's complete adjuvant (FCA). Secretion of the antigens was not necessary as tumour cells expressing a cell-surface antigen (HER-2/Neu) or an intracellular antigen green fluorescence protein (GFP) - also generated high-titre antigen-specific IgG antibodies. In interleukin-4 (IL-4)-deficient mice, both IgG1 and IgG2a were produced in response to OVA administered in FCA, whereas in response to tumour-produced antigen, the antibodies switched from predominantly IgG1 to IgG2a, indicating that the mechanisms responsible for antibody induction differed between these forms of immunization. In contrast to the line 1 and EMT6 turnouts, which are of BALB/c origin, OVA- or PSA-producing B16 melanoma cells, which are of C57BL/6 origin, failed to elicit antibody production. This was not the result of strain differences, as a similar finding was observed when the turnouts were grown in (BALB/c × C57BL/6)F1 mice, but appeared to be caused by intrinsic differences in the tumours. Furthermore, co-injection of both B16/OVA and line 1 tumours resulted in production of anti-OVA antibody, indicating that B16 tumours were not immunosuppressive, but instead line 1 tumours appear to exert an adjuvant effect.

UR - http://www.scopus.com/inward/record.url?scp=0035052853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035052853&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2567.2001.01213.x

DO - 10.1046/j.1365-2567.2001.01213.x

M3 - Article

C2 - 11328383

AN - SCOPUS:0035052853

VL - 102

SP - 486

EP - 497

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 4

ER -